Rapport Therapeutics (RAPP) Net Cash Flow (2023 - 2026)
Rapport Therapeutics (RAPP) has 4 years of Net Cash Flow data on record, last reported at $25.4 million in Q1 2026.
- On a quarterly basis, Net Cash Flow rose 3080.35% to $25.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.5 million, a 222.74% increase, with the full-year FY2025 number at -$4.2 million, up 68.82% from a year prior.
- Net Cash Flow reached $25.4 million in Q1 2026 per RAPP's latest filing, up from -$198.7 million in the prior quarter.
- Over the last five years, Net Cash Flow for RAPP hit a ceiling of $196.3 million in Q3 2025 and a floor of -$198.7 million in Q4 2025.
- A 4-year average of -$124272.7 and a median of $4.1 million in 2024 define the central range for Net Cash Flow.
- Peak YoY movement for Net Cash Flow: crashed 1236.09% in 2025, then surged 3080.35% in 2026.
- Tracing RAPP's Net Cash Flow over 4 years: stood at -$89.2 million in 2023, then surged by 119.62% to $17.5 million in 2024, then plummeted by 1236.09% to -$198.7 million in 2025, then skyrocketed by 112.79% to $25.4 million in 2026.
- Business Quant data shows Net Cash Flow for RAPP at $25.4 million in Q1 2026, -$198.7 million in Q4 2025, and $196.3 million in Q3 2025.